ArticleTheranostics2018
A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- YAP1 in control: how RNA networks and protein modifications shape its function and therapeutic targetability.Molecular cancer · 2026Review
- RHBDF1 modulates cisplatin sensitivity of small cell lung cancer through YAP1/Smad2 signaling pathway.Heliyon · 2024Article
- Non-Coding RNAs as Key Regulators in Lung Cancer.International journal of molecular sciences · 2023Review
- Role of microRNAs in glycolysis in gynecological tumors (Review).International journal of oncology · 2023Review
- High Expression of DNTTIP1 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma.Pharmacogenomics and personalized medicine · 2023Article
- Review
- MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells.Cell communication and signaling : CCS · 2022Review
- The importance of miRNA-630 in human diseases with an especial focus on cancers.Cancer cell international · 2022Review
- miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential.Frontiers in pharmacology · 2022Review
- MicroRNA cerebrospinal fluid profile during the early brain injury period as a biomarker in subarachnoid hemorrhage patients.Frontiers in cellular neuroscience · 2022Article
- Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy.International journal of molecular sciences · 2021Review
- Identifying the key microRNAs implicated in atrial fibrillation.Anatolian journal of cardiology · 2021Article
- Identification of HIPK3 as a potential biomarker and an inhibitor of clear cell renal cell carcinoma.Aging · 2021Article
- LncRNA LINC00857 regulates the progression and glycolysis in ovarian cancer by modulating the Hippo signaling pathway.Cancer medicine · 2020Article
- Resveratrol Inhibits the Tumorigenesis of Follicular Thyroid Cancer via ST6GAL2-Regulated Activation of the Hippo Signaling Pathway.Molecular therapy oncolytics · 2020Article
- The WW domains dictate isoform-specific regulation of YAP1 stability and pancreatic cancer cell malignancy.Theranostics · 2020Article
- A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance.Theranostics · 2020Article
- The Role of Photoactivated and Non-Photoactivated Verteporfin on Tumor.Frontiers in pharmacology · 2020Review
- microRNA Expression Profiling in Young Prostate Cancer Patients.Journal of Cancer · 2020Article
- Expression of miR-630 associated with tyrosine kinase inhibitor therapeutic response in lung adenocarcinoma cases.Journal of thoracic disease · 2019Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.